OB/GYN Clinical Alert – September 1, 2011
September 1, 2011
View Issues
-
Safety of Ultrasound
Two recent studies have re-energized discussion regarding the safety of ultrasound a subject that pops up periodically and then disappears until a new study surfaces. -
Oral Contraceptive Suppression of Ovarian Function in Obese Patients
In this double-blind protocol, normal-weight (body mass index [BMI] 19.0-24.9 kg/m2) and obese (BMI 30.0-39.9 kg/m2) women with regular periods and normal ovarian ultrasound took one of two types of oral contraceptives (OCPs): either 21-day monophasic pills with 20 mcg ethinyl estradiol/100 mcg levonorgestrel or 30 mcg ethinyl estradiol/150 mcg levonorgestrel. -
Screening for Ovarian Cancer: Could it Cause More Harm than Good?
Due to the frequent identification of metastatic disease at diagnosis and its high associated mortality, ovarian cancer has been the persistent focus of many screening efforts. -
Special Feature: Postmenopausal HRT: Where Do We Stand in 2011?
A quick search on pubmed finds 122 manuscripts published in the first half of 2011 that reference the Women's Health Initiative (WHI) study in the title, abstract, or as a keyword. -
Pharmacology Watch: ACEIs and ARBs Help Patients with Aortic Stenosis
In this issue: ACEI/ARB therapy for AS; safety alert issued for dronedarone; statins and cancer risk; nesiritide and heart failure; and FDA actions. -
Clinical Briefs in Primary Care supplement